carvedilol has been researched along with pentoxifylline in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Morita, M; Naito, Y; Niki, E; Yoshikawa, T | 1 |
| Bergemann, A; Candy, G; Sareli, P; Skudicky, D; Sliwa, K | 1 |
| Latini, R | 1 |
| Nessler, J; Skrzypek, A | 1 |
2 review(s) available for carvedilol and pentoxifylline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[The modern view on the role of inflammatory factors in chronic heart failure and possibilities of pharmacological modification].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; C-Reactive Protein; Carbazoles; Carvedilol; Chronic Disease; Cytokines; Etanercept; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Pentoxifylline; Platelet Aggregation Inhibitors; Propanolamines; Receptors, Tumor Necrosis Factor; Vasodilator Agents | 2003 |
1 trial(s) available for carvedilol and pentoxifylline
| Article | Year |
|---|---|
Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Digoxin; Double-Blind Method; Drug Therapy, Combination; Exercise Tolerance; fas Receptor; Female; Humans; Male; Middle Aged; Pentoxifylline; Propanolamines; Prospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha; Vasodilator Agents; Ventricular Function, Left | 2001 |
7 other study(ies) available for carvedilol and pentoxifylline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
Topics: Animals; Antioxidants; Antipyrine; Arachidonate 15-Lipoxygenase; Edaravone; Free Radicals; Hypochlorous Acid; Lipid Metabolism; Lipids; Mice; Oxidants; Oxidation-Reduction; Peroxides; Peroxynitrous Acid; Plasma; Probucol; Singlet Oxygen | 2016 |
[Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol. Results of a randomised study].
Topics: Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Humans; Pentoxifylline; Propanolamines; Randomized Controlled Trials as Topic; Vasodilator Agents | 2001 |